Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design,...

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors like Osimertinib are vital for non-small-cell lung cancer (NSCLC).
• Clinical resistance mutations in NSCLC and limited efficacy in EGFR-altered glioblastoma (GBM) necessitate new brain-penetrant inhibitors.
• Targeting EGFR mutations and brain metastases remains a significant challenge in cancer therapy.

Purpose of the Study:

• To design and synthesize novel brain-penetrant EGFR inhibitors.
• To evaluate their efficacy against resistant EGFR mutations and EGFR-driven brain tumors.
• To explore their potential as therapeutics for NSCLC and GBM.

Main Methods:

• Molecular modeling studies to understand EGFR tyrosine kinase interactions.
• Synthesis of 2-amino-4-(1H-imidazol)pyridine derivatives as potential EGFR inhibitors.
• In vitro kinase assays, cell proliferation assays, and in vivo xenograft studies.

Main Results:

• Compound 8m demonstrated potent inhibition against EGFR^L858R/T790M and EGFR^{L858R/T790M/C797S} mutations.
• 8m suppressed proliferation in NSCLC, GBM, and Ba/F₃-EGFR^{L858R/T790M/C797S} cells, showing high kinase selectivity and oral bioavailability.
• Significant tumor growth suppression in vivo in NSCLC xenografts and anti-tumor efficacy in an intracranial brain metastasis model.

Conclusions:

• The novel 2-amino-4-(1H-imidazol)pyridine derivatives represent a promising scaffold for developing EGFR inhibitors.
• Compound 8m is a potential therapeutic candidate for treating EGFR-mutant NSCLC, GBM, and brain metastases.
• Further development is warranted for inhibitors targeting EGFR^L858R/T790M, EGFR^{L858R/T790M/C797}, and EGFRvIII mutants.